Long-term safety and antiretroviral activity of hydroxyurea and didanosine in HIV-infected patients
Article Abstract:
Hydroxyurea can increase the effectiveness of didanosine in the treatment of HIV infection, according to a study of 65 HIV patients. The drugs are inexpensive and have few side effects.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals
Article Abstract:
Treatment of HIV infected individuals with didanosine (ddI) and hydroxyurea (HU) may reduce the amount of virus in the body and increase the CD4 cell count. For 90 days, 12 asymptomatic HIV positive patients received 400 milligrams/day of ddI and 1000 mg/day of HU. After treatment, 7 of the 12 patients did not have detectable virus in cultured peripheral blood mononuclear cells. In addition, the concentration of HIV RNA in the blood of all patients decreased, and in six patients became undetectable with an initial polymerase chain reaction. The CD4+ cell count increased in 11 of the 12 patients. The median CD4+ count was 343 cells/cubic millimeter at the beginning of treatment and 541 cells/cubic mm after 90 days. Side effects which occurred in isolated cases included digestive problems, mouth sores, and paralysis of the right arm.
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells per cubic millimeter
Article Abstract:
The AIDS drugs stavudine and didanosine appear to be effective when used together. In a study of 86 HIV patients, higher doses were most effective in suppressing the virus and increasing the number of CD4 T cells.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter
- Abstracts: Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study)
- Abstracts: Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1 infected patients
- Abstracts: Mode of delivery and postpartum morbidity among HIV-infected women: the Women and Infants Transmission Study. Multicenter review of protease inhibitors in 89 pregnancies
- Abstracts: Characterization of Nevirapine resistance mutations in women with subtype A Vs. D HIV-1 6-8 weeks after single-dose Nevirapine (HIVNET 012)